BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Eastern Cooperative Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00828009
First received: January 22, 2009
Last updated: September 16, 2014
Last verified: September 2014
  Purpose

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery.


Condition Intervention Phase
Lung Cancer
Biological: bevacizumab
Biological: emepepimut-S
Drug: carboplatin
Drug: cyclophosphamide
Drug: paclitaxel
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Resource links provided by NLM:


Further study details as provided by Eastern Cooperative Oncology Group:

Primary Outcome Measures:
  • Safety [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Progression-free survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]

Estimated Enrollment: 55
Study Start Date: December 2010
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To determine the safety of BLP25 liposome vaccine and bevacizumab after definitive chemoradiotherapy and consolidation chemotherapy in patients with newly diagnosed, unresectable stage IIIA or IIIB nonsquamous cell non-small cell lung cancer.

Secondary

  • To evaluate the overall survival and progression-free in patients treated with this regimen.
  • To evaluate the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

  • Chemoradiotherapy: Patients receive paclitaxel IV over 1 hour and carboplatin IV over 15-30 minutes once a week for 6 weeks. Patients also undergo concurrent definitive radiotherapy 5 days a week for 6½ weeks. Patients with complete response (CR), partial response (PR), or stable disease (SD) proceed to consolidation chemotherapy.
  • Consolidation chemotherapy: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR, PR, or SD proceed to maintenance therapy.
  • Maintenance therapy: Patients receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and BLP25 liposome vaccine. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and BLP25 liposome vaccine subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 5 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed newly diagnosed nonsquamous cell non-small cell lung cancer (NSCLC), including the following subtypes:

    • Adenocarcinoma
    • Large cell undifferentiated
    • Bronchoalveolar cell
    • NSCLC, not otherwise specified
  • Unresectable stage IIIA or stage IIIB disease

    • Patients with stage IIIA disease with mediastinal lymph node enlargement between 1 cm and 2.0 cm on CT scan must have these nodes biopsied (pathologic confirmation) to rule out resectability
    • Metastases to contralateral mediastinal or supraclavicular nodes allowed
  • Measurable or non-measurable disease, as defined by RECIST criteria
  • No significant pleural effusion as defined by either of the following:

    • Pleural effusion is seen on CT scan only (not seen on chest x-ray)
    • Pleural effusion does not reaccumulate within 1 week after thoracentesis AND is cytologically negative
  • No CNS metastases by head CT scan or MRI within the past 4 weeks

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • WBC ≥ 4,000/mm³ OR ANC ≥ 2,000/mm³
  • Platelet count ≥ 140,000/mm³
  • Hemoglobin ≥ 9.0 g/dL
  • Total bilirubin ≤ 1.5 mg/dL
  • AST/ALT ≤ 2.5 times upper limit of normal
  • Serum creatinine ≤ 1.5 mg/mL OR creatinine clearance ≥ 45 mL/min
  • Urine protein:creatinine ratio < 1.0 by urine dipstick OR < 1 g of protein by 24-hour urine collection
  • INR ≤ 1.5 OR ≤ 3.0 if patient is on therapeutic anticoagulation
  • PTT normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception before, during, and for ≥ 6 months after completion of bevacizumab
  • No other active malignancies
  • No known hepatitis B or C
  • No ongoing (lasting > 14 days) or active infection or ongoing (lasting > 14 days) fever within the past 6 months
  • No gross hemoptysis ≥ grade 2 (defined as ≥ ½ teaspoon of bright red blood per episode) within the past 3 months

    • No pulmonary hemoptysis

      • Confirmed extrapulmonary hemoptysis allowed
  • No bleeding ≥ grade 2 or any bleeding requiring intervention
  • No history of bleeding diathesis or coagulopathy
  • No cardiac dysfunction, including any of the following:

    • Clinically significant cardiovascular disease
    • Myocardial infarction within the past 6 months
    • New York Heart Association class III-IV congestive heart failure
    • Unstable angina pectoris
    • Serious cardiac arrhythmia requiring medication within the past 4 weeks
    • History of hypertensive crisis or hypertensive encephalopathy
    • Stroke or transient ischemic attack within the past 6 months
    • Peripheral vascular disease ≥ grade 2 within the past 6 months
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No psychiatric illness or social situation that would limit compliance with study requirements
  • No history of uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) while on stable regimen of antihypertensive therapy
  • No significant traumatic injury or serious non-healing wound, ulcer, or bone fracture within the past 4 weeks
  • No recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
  • No pre-existing medical condition requiring chronic steroids or immunosuppressive therapy
  • No autoimmune disease
  • No known hypersensitivity to any component of bevacizumab

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 4 weeks since prior open biopsy or major surgical procedure
  • More than 28 days since prior immunotherapy (e.g., interferon, interleukin, sargramostim [GM-CSF], or filgrastim [G-CSF])
  • Patients must not have had prior chemotherapy or monoclonal antibodies for other cancers within 5 years prior to registration
  • More than 7 says since prior core biopsy or any other minor surgical procedure, excluding the placement of a vascular access device
  • No prior chemotherapy for lung cancer
  • No prior chest radiotherapy
  • No prior splenectomy
  • Concurrent stable regimen of therapeutic anticoagulation or prophylactic anticoagulation for venous access devices allowed provided coagulation studies met entry criteria
  • No concurrent daily aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory agents (NSAIDs) known to inhibit platelet function
  • No concurrent dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel bisulfate (Plavix), and/or cilostazol (Pletal)
  • No concurrent major surgical procedure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00828009

  Hide Study Locations
Locations
United States, California
Veterans Affairs Medical Center - Palo Alto Recruiting
Palo Alto, California, United States, 94304
Contact: Heather A. Wakelee    650-493-5000      
Stanford Cancer Center Recruiting
Stanford, California, United States, 94305-5824
Contact: Clinical Trials Office - Stanford Cancer Center    650-498-7061    cctoffice@stanford.edu   
United States, Georgia
Medical Center of Central Georgia Recruiting
Macon, Georgia, United States, 31208
Contact: Frederick M. Schnell, MD, FACP    478-743-7068      
United States, Illinois
St. Joseph Medical Center Recruiting
Bloomington, Illinois, United States, 61701
Contact: John W. Kugler, MD    309-243-3605      
Graham Hospital Recruiting
Canton, Illinois, United States, 61520
Contact: John W. Kugler, MD    309-243-3605      
Memorial Hospital Recruiting
Carthage, Illinois, United States, 62321
Contact: John W. Kugler, MD    309-243-3605      
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Recruiting
Chicago, Illinois, United States, 60611-3013
Contact: Clinical Trials Office - Robert H. Lurie Comprehensive Cancer    312-695-1301    cancer@northwestern.edu   
Saint Joseph Hospital Recruiting
Chicago, Illinois, United States, 60657
Contact: Ira Oliff, MD    847-673-1999      
Hematology and Oncology Associates Recruiting
Chicago, Illinois, United States, 60611
Contact: Clinical Trails Office - Hematology and Oncology Associates    312-695-1301      
Decatur Memorial Hospital Cancer Care Institute Recruiting
Decatur, Illinois, United States, 62526
Contact: Clinical Trials Office - Decatur Memorial Hospital Cancer Care    217-876-4750      
Eureka Community Hospital Recruiting
Eureka, Illinois, United States, 61530
Contact: John W. Kugler, MD    309-243-3605      
Galesburg Clinic, PC Recruiting
Galesburg, Illinois, United States, 61401
Contact: John W. Kugler, MD    309-243-3605      
Ingalls Cancer Care Center at Ingalls Memorial Hospital Recruiting
Harvey, Illinois, United States, 60426
Contact: Clinical Trials Office - Ingalls Cancer Care Center at Ingalls    708-915-4673      
Mason District Hospital Recruiting
Havana, Illinois, United States, 62644
Contact: John W. Kugler, MD    309-243-3605      
Kellogg Cancer Care Center Recruiting
Highland Park, Illinois, United States, 60035
Contact: Jyoti D. Patel    312-695-4549      
Hinsdale Hematology Oncology Associates Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Elyse C. Schneiderman, MD    630-654-1790      
Provena St. Mary's Regional Cancer Center - Kankakee Recruiting
Kankakee, Illinois, United States, 60901
Contact: Jyoti D. Patel    312-695-4549      
North Shore Oncology and Hematology Associates, Limited - Libertyville Recruiting
Libertyville, Illinois, United States, 60048
Contact: Jyoti D. Patel    312-695-4549      
McDonough District Hospital Recruiting
Macomb, Illinois, United States, 61455
Contact: John W. Kugler, MD    309-243-3605      
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus Recruiting
Moline, Illinois, United States, 61265
Contact: Costas L. Constantinou, MD    563-359-9876      
Cancer Care and Hematology Specialists of Chicagoland - Niles Recruiting
Niles, Illinois, United States, 60714
Contact: Jyoti D. Patel    312-695-4549      
Community Cancer Center Recruiting
Normal, Illinois, United States, 61761
Contact: John W. Kugler, MD    309-243-3605      
BroMenn Regional Medical Center Recruiting
Normal, Illinois, United States, 61761
Contact: John W. Kugler, MD    309-243-3605      
Community Hospital of Ottawa Recruiting
Ottawa, Illinois, United States, 61350
Contact: John W. Kugler, MD    309-243-3605      
Cancer Treatment Center at Pekin Hospital Recruiting
Pekin, Illinois, United States, 61554
Contact: John W. Kugler, MD    309-243-3605      
OSF St. Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: John W. Kugler, MD    309-243-3605      
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61636
Contact: Clinical Trials Office - Methodist Medical Center of Illinois    309-243-3000      
Proctor Hospital Recruiting
Peoria, Illinois, United States, 61614
Contact: John W. Kugler, MD    309-243-3605      
Oncology Hematology Associates of Central Illinois, PC - Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: John W. Kugler, MD    309-243-3605      
CCOP - Illinois Oncology Research Association Recruiting
Peoria, Illinois, United States, 61615
Contact: John W. Kugler, MD    309-243-3605      
Illinois Valley Community Hospital Recruiting
Peru, Illinois, United States, 61354
Contact: John W. Kugler, MD    309-243-3605      
Perry Memorial Hospital Recruiting
Princeton, Illinois, United States, 61356
Contact: John W. Kugler, MD    309-243-3605      
Swedish-American Regional Cancer Center Recruiting
Rockford, Illinois, United States, 61104-2315
Contact: Clinical Trials Office - Swedish-American Regional Cancer Cent    815-489-4413      
Hematology Oncology Associates - Skokie Recruiting
Skokie, Illinois, United States, 60076
Contact: Jyoti D. Patel    312-695-4549      
Regional Cancer Center at Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781-0001
Contact: Clinical Trials Office - Regional Cancer Center at Memorial Me    217-788-4233      
United States, Indiana
Elkhart General Hospital Recruiting
Elkhart, Indiana, United States, 46515
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Howard Community Hospital Recruiting
Kokomo, Indiana, United States, 46904
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Center for Cancer Therapy at LaPorte Hospital and Health Services Recruiting
La Porte, Indiana, United States, 46350
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Saint Joseph Regional Medical Center Recruiting
Mishawaka, Indiana, United States, 46545-1470
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Cancer Center at Ball Memorial Hospital Recruiting
Muncie, Indiana, United States, 47303-3499
Contact: Clinical Trials Office - Cancer Center at Ball Memorial Hospit    765-281-2107      
CCOP - Northern Indiana CR Consortium Recruiting
South Bend, Indiana, United States, 46601
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Memorial Hospital of South Bend Recruiting
South Bend, Indiana, United States, 46601
Contact: Clinical Trials Office - Memorial Hospital of South Bend    800-284-7370      
United States, Iowa
McFarland Clinic, PC Recruiting
Ames, Iowa, United States, 50010
Contact: Clinical Trials Office - McFarland Clinic, PC    515-239-2621      
Medical Oncology and Hematology Associates - West Des Moines Recruiting
Clive, Iowa, United States, 50325
Contact: Robert J. Behrens    515-875-9713      
CCOP - Iowa Oncology Research Association Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-244-7586      
John Stoddard Cancer Center at Iowa Lutheran Hospital Recruiting
Des Moines, Iowa, United States, 50316
Contact: Clinical Trials Office - John Stoddard Cancer Center at Iowa L    515-241-8704      
John Stoddard Cancer Center at Iowa Methodist Medical Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Clinical Trials Office - John Stoddard Cancer Center at Iowa M    515-241-6727      
Medical Oncology and Hematology Associates at John Stoddard Cancer Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-282-2921      
Medical Oncology and Hematology Associates at Mercy Cancer Center Recruiting
Des Moines, Iowa, United States, 50314
Contact: Robert J. Behrens    515-643-8740      
Mercy Cancer Center at Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Robert J. Behrens    515-643-8206      
Mercy Medical Center - Sioux City Recruiting
Sioux City, Iowa, United States, 51102
Contact: Donald B. Wender, MD, PhD    712-252-0088      
Siouxland Hematology-Oncology Associates, LLP Recruiting
Sioux City, Iowa, United States, 51101
Contact: Donald B. Wender, MD, PhD    712-252-0088      
St. Luke's Regional Medical Center Recruiting
Sioux City, Iowa, United States, 51104
Contact: Donald B. Wender, MD, PhD    712-252-0088      
United States, Massachusetts
Tufts Medical Center Cancer Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Gary M. Strauss    617-636-6100      
United States, Michigan
Borgess Medical Center Recruiting
Kalamazoo, Michigan, United States, 49001
Contact: Raymond S. Lord, MD    269-373-7458      
Bronson Methodist Hospital Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord, MD    269-373-7458      
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007-3731
Contact: Clinical Trials Office - West Michigan Cancer Center    269-373-7458      
Lakeland Regional Cancer Care Center - St. Joseph Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
Lakeside Cancer Specialists, PLLC Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Jose A. Bufill, MD, FACP    574-234-5123      
United States, Nebraska
Cancer Resource Center - Lincoln Recruiting
Lincoln, Nebraska, United States, 68510
Contact: Gamini S. Soori, MD, FACP, FRCP, MBA    402-393-3110      
Alegant Health Cancer Center at Bergan Mercy Medical Center Recruiting
Omaha, Nebraska, United States, 68124
Contact: Clinical Trials Office - Alegant Health Cancer Center at Berge    402-398-6060      
CCOP - Missouri Valley Cancer Consortium Recruiting
Omaha, Nebraska, United States, 68106
Contact: Gamini S. Soori, MD, FACP, FRCP, MBA    402-393-3110      
Creighton University Medical Center Recruiting
Omaha, Nebraska, United States, 68131-2197
Contact: Clinical Trials Office - Creighton University Medical Center    402-280-4100      
Immanuel Medical Center Recruiting
Omaha, Nebraska, United States, 68122
Contact: Gamini S. Soori, MD, FACP, FRCP, MBA    402-393-3110      
Lakeside Hospital Recruiting
Omaha, Nebraska, United States, 68130
Contact: Gamini S. Soori, MD, FACP, FRCP, MBA    402-393-3110      
United States, New Jersey
Cancer Institute of New Jersey at Hamilton Recruiting
Hamilton, New Jersey, United States, 08690
Contact: Clinical Trials Office - Cancer Institute of New Jersey at Ham    609-631-6946      
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Clinical Trials Office - Cancer Institute of New Jersey    732-235-8675      
United States, New York
Stony Brook University Cancer Center Recruiting
Stony Brook, New York, United States, 11794-9446
Contact: Clinical Trials Office - Stony Brook University Cancer Center    800-862-2215      
United States, Ohio
Mercy Cancer Center at Mercy Medical Center Recruiting
Canton, Ohio, United States, 44708
Contact: Mitchell Haut, MD    330-453-9993      
Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44106-5065
Contact: Clinical Trials Office - Case Comprehensive Cancer Center    800-641-2422      
St. Rita's Medical Center Recruiting
Lima, Ohio, United States, 45801
Contact: Clinical Trials Office - St. Rita's Medical Center    419-226-9617      
United States, Pennsylvania
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18105
Contact: Eliot L. Friedman, MD    610-402-0512      
Geisinger Cancer Institute at Geisinger Health Recruiting
Danville, Pennsylvania, United States, 17822-0001
Contact: Clinical Trials Office - Geisinger Cancer Institute    570-271-5251      
PinnacleHealth Regional Cancer Center at Polyclinic Hospital Recruiting
Harrisburg, Pennsylvania, United States, 17110-2098
Contact: Oncology Clinical Trial Coordinator    717-782-4750      
Geisinger Hazleton Cancer Center Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Rajiv Panikkar    570-459-2901      
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033-0850
Contact: Clinical Trials Office - Penn State Hershey Cancer Institute a    717-531-3779    CTO@hmc.psu.edu   
Lewistown Hospital Recruiting
Lewistown, Pennsylvania, United States, 17044
Contact: Henry Wagner, MD    717-531-5471      
Pottstown Memorial Regional Cancer Center Recruiting
Pottstown, Pennsylvania, United States, 19464
Contact: Wei Song, MD, PhD    610-327-7555      
Geisinger Medical Group - Scenery Park Recruiting
State College, Pennsylvania, United States, 16801
Contact: Rajiv Panikkar    814-231-4560      
Mount Nittany Medical Center Recruiting
State College, Pennsylvania, United States, 16803
Contact: Henry Wagner, MD    717-531-5471      
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Clinical Trials Office - Frank M. and Dorothea Henry Cancer Ce    570-271-5251      
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232-6838
Contact: Clinical Trials Office - Vanderbilt-Ingram Cancer Center    800-811-8480      
United States, Texas
Parkland Memorial Hospital Recruiting
Dallas, Texas, United States, 75235
Contact: Joan H. Schiller, MD    214-648-4180      
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Clinical Trials Office - Simmons Comprehensive Cancer Center a    866-460-4673; 214-648-7097      
United States, West Virginia
West Virginia University Health Sciences Center - Charleston Recruiting
Charleston, West Virginia, United States, 25304
Contact: Steven J. Jubelirer, MD    304-388-8380      
United States, Wisconsin
Gundersen Lutheran Center for Cancer and Blood Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Clinical Trials Office - Gundersen Lutheran Cancer Center    608-775-2385    cancerctr@gundluth.org   
Regional Cancer Center at Oconomowoc Memorial Hospital Recruiting
Oconomowoc, Wisconsin, United States, 53066
Contact: Clinical Trials Office - Regional Cancer Center at Oconomowoc    262-928-7878      
Waukesha Memorial Hospital Regional Cancer Center Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Clinical Trials Office - Waukesha Memorial Hospital Regional C    262-928-7632      
Sponsors and Collaborators
Eastern Cooperative Oncology Group
Investigators
Study Chair: Jyoti D. Patel Robert H. Lurie Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT00828009     History of Changes
Other Study ID Numbers: CDR0000632611, E6508
Study First Received: January 22, 2009
Last Updated: September 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Eastern Cooperative Oncology Group:
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
adenocarcinoma of the lung
bronchoalveolar cell lung cancer
large cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Bevacizumab
Cyclophosphamide
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists

ClinicalTrials.gov processed this record on September 18, 2014